Octapharma USA Requests FDA Approval for wilate® VWD Prophylaxis Supplement (IMAGE)

Yankee Public Relations

Octapharma USA Requests FDA Approval for wilate® VWD Prophylaxis Supplement

Caption

Octapharma USA has submitted a Biologics License Application Supplement (sBLA) to the U.S. Food and Drug Administration (FDA) to expand the approval of wilate®, von Willebrand Factor/Coagulation Factor VIII Complex (Human) Lyophilized Powder for Solution for Intravenous Injection, to include routine prophylaxis to reduce the frequency of bleeding episodes in children and adults with any type of von Willebrand disease (VWD).

Credit

Octapharma USA

Usage Restrictions

N/A

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.